You are now leaving Lundbeck.com/sg/en.

Cancel

Lundbeck partners with Zuellig Pharma

Lundbeck has entered into a partnership with Zuellig Pharma to continue bringing our medicines to patients and healthcare professionals in Singapore. Continuity of care remains our top priority, and together with Zuellig, we are ensuring access to Lundbeck’s medicines and ongoing support for patients and healthcare professionals.

 

For more information about Zuellig, please visit https://www.zuelligpharma.com. For specific enquiries, please see below.

 

 

Enquiries concerning Abilify, Abilify Maintena, Abilify Asimtufii, or Rexulti

If you are seeking to report adverse events or submit product quality complaints, please contact: sgop-pv@sg.otsuka.com

If you want to submit a medical enquiry, please contact: medical.information@apac.otsuka.com

 

 

Enquiries concerning all other products

If you are seeking to report adverse events or submit product quality complaints, please contact: SGZPSPVReporting@zuelligpharma.com

If you want to submit a medical enquiry, please contact: medinfo@zuelligpharma.com

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Lundbeck at a glance